Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective

Mickael Hiligsmann*, Setareh A. Williams, Lorraine A. Fitzpatrick, Stuart S. Silverman, Richard Weiss, Jean-Yves Reginster

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Pages (from-to)394-400
Number of pages7
JournalSeminars in Arthritis and Rheumatism
Volume50
Issue number3
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Abaloparatide
  • Alendronate
  • Economic evaluation
  • Monotherapy
  • Osteoporosis
  • Sequential treatmen
  • QUALITY-OF-LIFE
  • POSTMENOPAUSAL WOMEN
  • ORAL BISPHOSPHONATES
  • VERTEBRAL FRACTURES
  • SEVERE OSTEOPOROSIS
  • ECONOMIC-EVALUATION
  • EXCESS MORTALITY
  • UNITED-STATES
  • HIP FRACTURE
  • HEALTH

Cite this